These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7152425)

  • 1. [Changes in lymphocytes caused by aldosterone and a spironolactone derivative. Animal experiments and clinical studies].
    Liebich HG; Mertin J; Seifert J
    Fortschr Med; 1982 Nov; 100(41):1922-5. PubMed ID: 7152425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spirolactones: clinical and pharmacologic studies.
    Corvol P; Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Menard J
    Adv Nephrol Necker Hosp; 1977; 7():199-215. PubMed ID: 208407
    [No Abstract]   [Full Text] [Related]  

  • 3. Potassium prorenoate: a new steroidal aldosterone antagonist.
    Hofmann LM; Chinn LJ; Pedrera HA; Krupnick MI; Suleymanov OD
    J Pharmacol Exp Ther; 1975 Aug; 194(2):450-6. PubMed ID: 1151770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [EEG changes following spirolactone treatment (author's transl)].
    Simon O; Mertin J; Brass B
    Med Klin; 1978 Mar; 73(13):470-3. PubMed ID: 634207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma digoxin radioimmunoassay in patients treated with potassium canrenoate and spironolactone. A comparison of two commerical kits.
    Cristodorescu R; Gavrilescu S; Deutsch G; Berger E
    Agressologie; 1978; 19(6):409-14. PubMed ID: 751526
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of potassium-canrenoate on 3H-noradrenaline uptake and metabolism of the rat heart.
    Préda I; Sebeszta M; Harsányi A; Szabó G; Antalóczy Z
    Acta Physiol Acad Sci Hung; 1978; 51(4):393-9. PubMed ID: 754480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
    Tosti-Croce C; Mantellini R; Fanti P; Sciarra F
    Minerva Med; 1983 Apr; 74(14-15):791-7. PubMed ID: 6339999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium excretion and sodium-free volume expansion in dogs: effect of inhibition of aldosterone activity by canrenoate.
    Bie P
    Acta Physiol Scand; 1976 Oct; 98(2):272-4. PubMed ID: 983738
    [No Abstract]   [Full Text] [Related]  

  • 10. Antioestrogenic action of the aldosterone antagonist canrenoate K in the rat (adenohypophysis, ceruloplasmin).
    Schreiber V; Pribyl T
    Physiol Bohemoslov; 1977; 26(5):385-95. PubMed ID: 144921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of oral spironolactone and intravenous canrenoate-K on the digoxin radioimmunoassay.
    Lichey J; Schröder R; Rietbrock N
    Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):557-9. PubMed ID: 598949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S; Buch J
    Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 14. [Aldosterone antagonists in coronary insufficiency].
    Osswald H
    Med Klin; 1978 Jan; 73(3):84-8. PubMed ID: 622061
    [No Abstract]   [Full Text] [Related]  

  • 15. Involvement of cytochrome P-450IIIA in metabolism of potassium canrenoate to an epoxide: mechanism of inhibition of the epoxide formation by spironolactone and its sulfur-containing metabolite.
    Cook CS; Hauswald C; Oppermann JA; Schoenhard GL
    J Pharmacol Exp Ther; 1993 Jul; 266(1):1-7. PubMed ID: 8331551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of potassium-canrenoate in the 3H-noradrenaline uptake and metabolism of the rat heart.
    Préda I; Sebeszta M; Antalóczy Z
    Arzneimittelforschung; 1980; 30(3):436-8. PubMed ID: 7387752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical study of potassium canrenoate on raised intracranial pressure.
    Node Y; Nakazawa S
    Adv Neurol; 1990; 52():557. PubMed ID: 2396562
    [No Abstract]   [Full Text] [Related]  

  • 18. [Interference of canrenoate potassium with plasma renin activity. Note I. Effects of canrenoate potassiumon plasma renin activity in patients with essential hypertension].
    Consolo F; Ferraù O; Pitrone F; Luzza G; Russo A; Virga T
    Boll Soc Ital Biol Sper; 1975 Dec; 51(24):1943-9. PubMed ID: 1231877
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells.
    Hansen PR; Rieneck K; Bendtzen K
    Immunol Lett; 2004 Feb; 91(2-3):87-91. PubMed ID: 15019274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.